The non hormonal contraceptives market is expected to reach USD 1.8 billion in 2021 and anticipated to grow at a CAGR of 22% during the forecast period 2021-2030.

According to the World Health Organization (WHO), around one-third of clinical conditions prevalent among females aged 15 to 44 are linked to sexual and reproductive health. The complex female reproductive system operates under the influence of estrogen and progesterone. Imbalances in these hormones can lead to various ailments, mood disturbances, and unexplained physical symptoms, more prevalent in females than males. Since the 1960s, interventions regulating hormones have been developed and used, gaining widespread acceptance after demonstrating effectiveness in late 1990s clinical trials. However, subsequent studies have uncovered a correlation between these interventions and unwanted side effects, such as an elevated risk of hormone-dependent cancers.

Recent strides in non-hormonal contraceptives have revolutionized women’s healthcare. Brisdelle?, approved in 2013 for managing menopausal hot flashes, signaled the advent of such non-hormonal contraceptives. Currently, 21 non-hormonal contraceptives (e.g., Oriahnn?, Phexxi?, and Esmya?) have obtained approval. Furthermore, several non-hormonal birth control options are undergoing evaluation at various developmental stages. Clinical trials and post-approval studies have underscored the inherent advantages of non-hormonal birth control, including a superior safety profile, preservation of hormonal equilibrium, and shorter treatment durations compared to hormonal therapies. Consequently, non-hormonal contraceptives are now preferred over hormone-based treatments, and the pipeline for non-hormonal birth control is expected to steadily expand.

This market has witnessed substantial collaboration among stakeholders to strategically support ongoing product development and commercialization endeavors. The promising outcomes anticipated from ongoing clinical research are likely to attract more investments, driving the development of products in this burgeoning market segment. Consequently, substantial market growth is expected in this domain during the forecast period.

Report Coverage
? The report conducts an analysis of the non-hormonal contraceptive market, focusing on target indications, molecule types, therapeutic purposes, therapy mechanisms, administration routes, and key geographical regions.
? It examines factors such as drivers, restraints, opportunities, and challenges influencing market growth.
? Assessment of potential advantages and hurdles within the market is provided, along with insights into the competitive landscape for leading market players.
? Revenue forecasts for market segments are presented concerning three major regions.
? A comprehensive exploration of the current market landscape for non-hormonal therapies, including their developmental phases, molecular classifications, target indications, therapeutic objectives, target populations, mechanisms of action, routes of administration, and any special drug designations received.
? Detailed profiling of entities involved in developing non-hormonal therapies, outlining establishment years, company sizes, headquarters locations, and regional presence.
? In-depth discussion of diverse commercialization strategies applicable to drug developers in the non-hormonal contraceptives market, tailored to different stages of therapy development from pre-launch to post-marketing phases.
? Detailed profiles of phase III non-hormonal therapies, encompassing concise overviews, developmental status, administration routes, primary indications, dosages, mechanisms of action, clinical trials, trial outcomes, collaborations, and special drug designations.
? Meticulous analysis of geographical clinical trials, covering completed and ongoing studies of non-hormonal therapies, considering parameters such as trial registration year, status, phase, indications, geographic locations, sponsor types, treatment sites, and enrolled patient populations.
? Evaluation of partnerships established by stakeholders involved in non-hormonal therapy development from pre-2013 to 2020, inclusive of research agreements, R&D partnerships, manufacturing contracts, licensing deals, and other collaborations. Additionally, a detailed examination of investments made, including awards/grants, financing sources like venture capital, debt financing, and other financial contributions in companies engaged in the non-hormonal birth control market.

Key Market Companies
? AbbVie
? Adjuvant Capital
? Amgen
? Astellas Pharma
? Bayer
? Boehringer Ingelheim
? Cidara Therapeutics
? Eli Lilly